The Food and Drug Administration said a Covid-19 antibody treatment from Eli Lilly & Co. is no longer authorized for use because it isn’t likely to be effective against certain Omicron offshoots now dominant in the U.S.
from Eli Lilly & Co. is no longer authorized for use because it isn’t likely to be effective against certain Omicron offshoots now dominant in the U.S.
, now cause more than half of new Covid-19 cases in the U.S., the FDA said on Wednesday. Yet Lilly’s drug, bebtelovimab, doesn’t retain neutralizing activity against the subvariants, the company said.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Survey: How many people plan to get the bivalent COVID-19 omicron booster shot?The elderly are at higher risk for severe COVID-19. In the BW poll, 63.7% said they would get the booster, while 17.9% said no and 18.5% were unsure.
Leer más »
COVID hospitalization rates in babies as bad as for seniors amid Omicron wave, study showsThe findings, published by the U.S. Centers for Disease Control and Prevention, show that COVID-19 can still cause severe and fatal outcomes in children too young to be vaccinated.
Leer más »
Can China end its ‘zero COVID’ policy — and minimize COVID deaths?Vaccinating more older people, stocking up on antiviral drugs and expanding hospital facilities would help to ease the transition away from zero COVID.
Leer más »
Diabetes Drug Metformin Might Keep Severe COVID AwayA century-old diabetes drug seems to help keep high-risk COVID-19 patients from falling deathly ill, a new study reports.
Leer más »